AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampli

AIM ImmunoTech Inc. (NYSE American: AIM) has commenced its Phase 2 study to evaluate the potential therapeutic effects of Ampligen® on individuals with post-COVID conditions. The enrollment and dosing of the first subject have already taken place, with encouraging preliminary data on Ampligen. The study is projected to be fully enrolled by Q4 2023. In order to facilitate this study, AIM has esta..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 11.
  • textsms

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

Celldex Therapeutics, Inc. has announced that the first patient has been dosed in their Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). EoE is a chronic inflammatory disease of the esophagus and the most common type of eosinophilic gastrointestinal disease. The study aims to evaluate the efficacy and safety profile of subcutaneous barzolvolimab in patients with active EoE. The ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 7.
  • textsms

AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination

AEON Biopharma and Priveterra have announced the arrangement of up to $125 million in financing for their proposed business combination. The funding includes $50 million from existing and new AEON investors, as well as cash from Priveterra's trust account. This funding will allow AEON to continue its development of a botulinum toxin complex for the treatment of medical conditions, including migr..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms